Načítá se...
Development of PROSTVAC immunotherapy in prostate cancer
PROSTVAC immunotherapy is a heterologous prime-boost regimen of two different recombinant pox-virus vectors; vaccinia as the primary immunotherapy, followed by boosters employing fowlpox, to provoke immune responses against prostate-specific antigen. Both vectors contain transgenes for prostate-spec...
Uloženo v:
| Vydáno v: | Future Oncol |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4544699/ https://ncbi.nlm.nih.gov/pubmed/26235179 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon.15.120 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|